Abstract: Mutations in the RNase IIIb domain of DICER1 are known to disrupt processing of 5p-strand pre-miRNAs and these mutations have previously been associated with cancer. Using data from the Cancer Genome Atlas project, we show that these mutations are recurrent across four cancer types and that a previously uncharacterized recurrent mutation in the adjacent RNase IIIa domain also disrupts 5p-strand miRNA processing. Analysis of the downstream effects of the resulting imbalance 5p/3p shows a statistically significant effect on the expression of mRNAs targeted by major conserved miRNA families. In summary, these mutations in DICER1 lead to an imbalance in miRNA strands, which has an effect on mRNA transcript levels that appear to contribute to the oncogenesis.
Introduction
MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression post-transcriptionally. They are produced by the enzyme DICER1, which processes precursor molecules into two mature strands: the 5p and the 3p strand. Under normal physiological conditions, these strands are produced in a regulated balance.
While mutations in the RNase IIIb domain of DICER1 have been linked to specific cancers, the broader prevalence of these mutations across different tumor types and their functional impact on the human transcriptome remained poorly understood. This study investigates how recurrent "hotspot" mutations in DICER1 disrupt miRNA processing and drive oncogenesis by altering the expression of key target genes.
Methods
The authors employed a multi-omic approach using data from The Cancer Genome Atlas (TCGA), analyzing 5,535 sequenced tumor samples across 14 cancer types. Key methodologies included:
- Genomic Screening: Identifying recurrent mutations within the DICER1 gene.
- miRNA-Seq Analysis: Quantifying the ratio of 5p to 3p strands ($m_{5,3} = \log_2(m_5/m_3)$) to detect processing imbalances.
- Structural Modeling: Utilizing 3D protein modeling and Evolutionary Couplings (ECs) via the EVFold server to map the functional proximity of mutated residues.
- Transcriptomics: Performing differential gene expression analysis and Gene Set Enrichment Analysis (GSEA) to identify mRNA pathways affected by miRNA strand depletion.
Key Results
Identification of the S1344L "Cross-Talk" Mutation
The study identified recurrent hotspot mutations in the RNase IIIb domain and a previously uncharacterized recurrent mutation in the RNase IIIa domain, S1344L. Although the IIIa domain typically handles 3p processing, structural analysis revealed that S1344 sits adjacent to the IIIb active site in the DICER1 heterodimer. This proximity explains why the S1344L mutation mimics the effects of IIIb mutations, leading to 5p strand depletion.
Significant 5p miRNA Depletion
Hotspot mutants exhibited a massive, statistically significant drop in 5p miRNA expression compared to 3p strands ($p < 10^{-29}$). This imbalance was consistent across multiple cancer types, including Uterine Corpus Endometrial Carcinoma (UCEC) and Thyroid Carcinoma (THCA).
Oncogene Activation and Pathway Dysregulation
The depletion of 5p strands has profound functional consequences. Major 5p-dominant miRNA families, such as let-7, are lost in these mutants. Since let-7 normally suppresses oncogenes, its absence leads to the upregulation of drivers like HMGA2. GSEA confirmed that genes trending upward in mutant tumors were specifically those targeted by the depleted 5p miRNA families, providing a direct link between DICER1 mutations and oncogenic transcriptomic shifts.
Discussion
These findings demonstrate that recurrent mutations in the RNase III domains of DICER1—including the newly identified S1344L mutation—act as a molecular switch that depletes 5p miRNAs. This "strand imbalance" effectively removes the regulatory brakes on key oncogenes, contributing to tumor development. Most hotspot mutants were found to be biallelic, suggesting that the loss of wild-type DICER1 function is a critical step in this oncogenic process. While limited by the sample size of specific mutant cohorts, the study provides a clear mechanistic framework for how DICER1 mutations shape the molecular landscape of human tumors.
Summary updated